Welcome to LookChem.com Sign In|Join Free

CAS

  • or
4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE is a chemical compound characterized by its thiazole-pyridine structure. It is an amine derivative that holds significant potential in the field of medicinal chemistry, particularly for the development of therapeutic agents. 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE has demonstrated properties as a central nervous system depressant and has been the subject of research for its potential in treating neurological disorders. Its exploration also extends to anti-inflammatory and antiviral applications, with its unique structure attracting interest for further pharmaceutical research and development.

97817-23-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 97817-23-7 Structure
  • Basic information

    1. Product Name: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE
    2. Synonyms: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE;4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-amine(SALTDATA: FREE);2-Amino-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine;4,5,6,7-Tetrahydrothiazolo[5,4-c]pyridin-2-amine;Thiazolo[5,4-c]pyridin-2-aMine, 4,5,6,7-tetrahydro-
    3. CAS NO:97817-23-7
    4. Molecular Formula: C6H9N3S
    5. Molecular Weight: 155.22076
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 97817-23-7.mol
  • Chemical Properties

    1. Melting Point: 195℃
    2. Boiling Point: 353℃
    3. Flash Point: 167℃
    4. Appearance: /
    5. Density: 1.323
    6. Vapor Pressure: 3.65E-05mmHg at 25°C
    7. Refractive Index: 1.644
    8. Storage Temp.: 2-8°C(protect from light)
    9. Solubility: N/A
    10. CAS DataBase Reference: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE(CAS DataBase Reference)
    11. NIST Chemistry Reference: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE(97817-23-7)
    12. EPA Substance Registry System: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE(97817-23-7)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 97817-23-7(Hazardous Substances Data)

97817-23-7 Usage

Uses

Used in Pharmaceutical Industry:
4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE is used as a potential therapeutic agent for the development of medications targeting neurological disorders. Its central nervous system depressant properties make it a candidate for conditions that require such therapeutic intervention.
Used in Neurological Disorder Treatment:
In the field of neurology, 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE is used as a potential treatment for neurological disorders due to its demonstrated effects on the central nervous system, offering a new avenue for managing such conditions.
Used in Anti-Inflammatory Applications:
4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE is also considered for its anti-inflammatory potential, suggesting its use in treating conditions characterized by inflammation, where modulation of the immune response is required.
Used in Antiviral Research:
Furthermore, 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE is used in antiviral research, exploring its capacity to inhibit viral replication or activity, which could lead to new treatments for viral infections.

Check Digit Verification of cas no

The CAS Registry Mumber 97817-23-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,8,1 and 7 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 97817-23:
(7*9)+(6*7)+(5*8)+(4*1)+(3*7)+(2*2)+(1*3)=177
177 % 10 = 7
So 97817-23-7 is a valid CAS Registry Number.
InChI:InChI=1/C6H9N3S/c7-6-9-4-1-2-8-3-5(4)10-6/h8H,1-3H2,(H2,7,9)

97817-23-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine

1.2 Other means of identification

Product number -
Other names 4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-amine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:97817-23-7 SDS

97817-23-7Relevant articles and documents

Preparation 2 - amino - 5 - CBZ - 4, 5, 6, 7 - tetrahydro-thiazolo [5, 4 - C] pyridine of the new method (by machine translation)

-

Paragraph 0012; 0014, (2019/01/23)

The invention discloses a process for preparing 2 - amino - 5 - CBZ - 4, 5, 6, 7 - tetrahydro-thiazolo [5, 4 - C] pyridine of the new method, comprises the following steps: N - tert-butoxycarbonyl - 4 - piperidone in pyridine with sulfur and single cyanamide mixed heating reaction→cooling→filtering→washed with an organic solvent, and dried to obtain a pale yellow solid product→in dichloromethane in trifluoroacetic acid is mixed with low-temperature reaction, concentrated→with triethylamine in dichloromethane in the mixed low-temperature drop chlorination benzyl formate, stirring reaction→[...]→dichloromethane extraction, the organic phase water, salt water washing, drying, filtering and concentrated to obtain crude product→ethyl acetate beating, the final product is obtained yellow solid. The invention of cheap price for raw materials to replace the original high price of the raw material for preparing the final product, to avoid the original ring-brominated by-product when many routes, not only the operation is simple, convenient purification, the cost is reduced, high yield, favorable to the industrialized production and cost control. (by machine translation)

Thiazolopyridines Improve Adipocyte Function by Inhibiting 11 Beta-HSD1 Oxoreductase Activity

Rathinasabapathy, Thirumurugan,Palatini Jackson, Kimberly Marie,Thor, Yiwen,Buru, Ayuba Sunday,Esposito, Debora,Li, Xu,Pichika, Mallikarjuna Rao,Hamzah, Ahmad Sazali,Komarnytsky, Slavko

, (2017/04/28)

Background. Glucocorticoid excess has been linked to clinical observations associated with the pathophysiology of metabolic syndrome. The intracellular glucocorticoid levels are primarily modulated by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme that is highly expressed in key metabolic tissues including fat, liver, and the central nervous system. Methods. In this study we synthesized a set of novel tetrahydrothiazolopyridine derivatives, TR-01-4, that specifically target 11β-HSD1 and studied their ability to interfere with the glucocorticoid and lipid metabolism in the 3T3-L1 adipocytes. Results. Based on the docking model and structure-activity relationships, tetrahydrothiazolopyridine derivatives TR-02 and TR-04 showed the highest potency against 11β-HSD1 by dose-dependently inhibiting conversion of cortisone to cortisol (IC50 values of 1.8 μM and 0.095 μM, resp.). Incubation of fat cells with 0.1-10 μM TR-01-4 significantly decreased cortisone-induced lipid accumulation in adipocytes and suppressed 11β-HSD1 mRNA expression. Observed reduction in adipocyte fat stores could be partially explained by decreased expression levels of adipogenic markers (PPAR-γ, aP2) and key enzymes of lipid metabolism, including fatty acid synthase (FAS), hormone sensitive lipase (HSL), and lipoprotein lipase (LPL). Conclusions. The tetrahydrothiazolopyridine moiety served as an active pharmacophore for inhibiting 11β-HSD1 and offered a novel therapeutic strategy to ameliorate metabolic alterations found in obesity and diabetes.

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Wang, Zhengyu,Shi, Xiaofan,Zhang, Huan,Yu, Liang,Cheng, Yanhua,Zhang, Hefeng,Zhang, Huibin,Zhou, Jinpei,Chen, Jing,Shen, Xu,Duan, Wenhu

, p. 128 - 152 (2017/08/10)

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

-

Paragraph 0126; 0127, (2014/08/06)

The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders).

Heterocycylic-substituted quinoline-carboxylic acids

-

, (2008/06/13)

1-Substituted-6-fluoro-7-heterocyclic-1,4-dihydroquino-1-(or dihydronaphthyridin)-4-one carboxylic acids have antibacterial properties. The 7-heterocyclic group is a bicyclic group, one of the rings of which is saturated and the other ring of which is unsaturated.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 97817-23-7